Somatostatin Receptor Radionuclide Theranostics using [67Cu]Cu-NODAGA-TATE – Insights from Phaeochromocytoma Models

Ziel/Aim Advances in the production of 67Cu have augmented its potential use for targeted cancer therapies including peptide receptor radionuclide therapy. This study compared the anti-tumour effects of the radiolabelled (Tyr3) octreotate derivatives [67Cu]Cu-NODAGA-TATE and [177Lu]Lu-DOTA-TATE in somatostatin type 2 receptor (SSTR2) expressing mouse phaeochromocytoma (MPC) tumour spheroids and allograft mice.